Abstract
Mycosis fungoides is the most common form of cutaneous T cell lymphoma. Although normally presenting to physicians at an early stage and with an indolent course, mycosis fungoides can have a varied presentation. The National Comprehensive Cancer Network (NCCN) has created guidelines for the treatment and staging of mycosis fungoides. Although comprehensive, in practice these guidelines do not provide specific treatment regimens for lesions located in difficult locations and those recalcitrant to the recommended therapy. Because of this, suggestions based on the practices and decisions made at the multidisciplinary cutaneous lymphoma clinic at the Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, PA, USA, are presented here. Lesions located in areas such as the face and intertriginous zones are often challenging to treat because first-line therapies are often inappropriate, with the locations increasing the possibility of side effects. Additionally, lesions located in the bathing suit distribution are often nonresponsive to first-line therapies for reasons still undetermined. Finally, although well-described, erythroderma secondary to mycosis fungoides is challenging to treat, with controversy surrounding various methods of control. This article both highlights difficult clinical scenarios and reviews the recommended treatment as provided by the NCCN guidelines and provides alternative therapy for lesions that are either difficult to treat because of the location or are recalcitrant to the recommended therapy. With suggestions for the apparent gaps in guidelines, providers can better treat patients who present with more complicated conditions.
Similar content being viewed by others
References
National Comprehensive Cancer Network. Mycosis Fungoides/Sezary Syndrome. (Version 4.2018). https://www.nccn.org/professionals/physician_gls/pdf/t-cell.pdf. Accessed 3 July 2018.
Wilcox RA. Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management. Am J Hematol. 2016;91(1):151–65. https://doi.org/10.1002/ajh.24233.
Ahmad K, Rogers S, McNicholas PD, Collins P. Narrowband UVB and PUVA in the treatment of mycosis fungoides: a retrospective study. Acta Derm Venereol. 2007;87(5):413–7.
Clobetasol. Lexi-Drugs. Lexicomp. Wolters Kluwer Health, Inc. Riverwoods. http://online.lexi.com. Accessed 28 July 2018.
Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: along overdue revisit. Indian Dermatol Online J. 2014;5(4):416–25. https://doi.org/10.4103/2229-5178.142483.
Valchlor [package insert]. Malvern, PA: Ceptaris Therapeutics, Inc.; 2013.
Targretin [package insert]. San Diego: Ligand Pharmaceuticals Inc.
Gül U, Soylu S, Aslan E, Yazar Z, Demiriz M. Uncommon presentation of mycosis fungoides: eyelid margin involvement. J Dermatol. 2008;35(9):581–4. https://doi.org/10.1111/j.13468138.2008.00526.
Metin A, Dilek N, Demirseven DD. Fungal infections of the folds (intertriginous areas). Clin Dermatol. 2015;33(4):437–47. https://doi.org/10.1016/j.clindermatol.
Martin SJ, Duvic M. Prevalence and treatment of palmoplantar keratoderma and tinea pedis in patients with Sézary syndrome. Int J Dermatol. 2012;51(10):1195–8. https://doi.org/10.1111/j.1365-4632.2011.05204.
Olsen EA, Hodak E, Anderson T, Carter JB, Henderson M, Cooper K, Lim HW. Guidelines for phototherapy of mycosis fungoides and Sézary syndrome: a consensus statement of the United States Cutaneous Lymphoma Consortium. J Am Acad Dermatol. 2016;74(1):27–58. https://doi.org/10.1016/j.jaad.2015.09.033.
Chan DV, Aneja S, Honda K, Carlson S, Yao M, Katcher J, Cooper KD. Radiation therapy in the management of unilesional primary cutaneous T-cell lymphomas. Br J Dermatol. 2012;166(5):1134–7. https://doi.org/10.1111/j.1365-2133.2011.10728.
Wilson LD, Kacinski BM, Jones GW. Local superficial radiotherapy in the management of minimal stage IA cutaneous T-cell lymphoma (Mycosis Fungoides). Int J Radiat Oncol Biol Phys. 1998;40(1):109–15.
Piccinno R, Caccialanza M, Percivalle S. Minimal stage IA mycosis fungoides. Results of radiotherapy in 15 patients. J Dermatolog Treat. 2009;20(3):165–8. https://doi.org/10.1080/09546630802516571.
Cotter GW, Baglan RJ, Wasserman TH, Mill W. Palliative radiation treatment of cutaneous mycosis fungoides–a dose response. Int J Radiat Oncol Biol Phys. 1983;9(10):1477–80.
Neelis KJ, Schimmel EC, Vermeer MH, Senff NJ, Willemze R, Noordijk EM. Low-dose palliative radiotherapy for cutaneous B- and T-cell lymphomas. Int J Radiat Oncol Biol Phys. 2009;74(1):154–8. https://doi.org/10.1016/j.ijrobp.2008.06.1918.
Thomas TO, Agrawal P, Guitart J, Rosen ST, Rademaker AW, Querfeld C, Hayes JP, Kuzel TM, Mittal BB. Outcome of patients treated with a single-fraction dose of palliative radiation for cutaneous T-cell lymphoma. Int J Radiat Oncol Biol Phys. 2013;85(3):747–53. https://doi.org/10.1016/j.ijrobp.2012.05.034.
Lichter MD, Karagas MR, Mott LA, Spencer SK, Stukel TA, Greenberg ER. Therapeutic ionizing radiation and the incidence of basal cell carcinoma and squamous cell carcinoma. The New Hampshire Skin Cancer Study Group. Arch Dermatol. 2000 Aug;136(8):1007-11.
Akhyani M, Ghodsi ZS, Toosi S, Dabbaghian H. Erythroderma: a clinical study of 97 cases. BMC Dermatol. 2005;9(5):5.
César A, Cruz M, Mota A, Azevedo F. Erythroderma. A clinical and etiological study of 103 patients. J Dermatol Case Rep. 2016 Mar 31;10(1):1-9. https://doi.org/10.3315/jdcr.2016.1222.
Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008;159(1):105–12. https://doi.org/10.1111/j.1365-2133.2008.08612.
Hoppe RT, Harrison C, Tavallaee M, Bashey S, Sundram U, Li S, Million L, Dabaja B, Gangar P, Duvic M, Kim YH. Low-dose total skin electron beam therapy as an effective modality to reduce disease burden in patients with mycosis fungoides: results of a pooled analysis from 3 phase-II clinical trials. J Am Acad Dermatol. 2015;72(2):286–92. https://doi.org/10.1016/j.jaad.2014.10.014.
Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin Pharmacother. 2006;7(7):907–15.
Strander H. Interferon treatment of human neoplasia. Adv Cancer Res. 1986;46:1–265.
Isaacs A, Lindenmann J. Virus interference. I. the interferon. Proc R Soc Lond B Biol Sci 1957;147:258–67.
Roth MS, Foon KA. Alpha interferon in the treatment of hematologic malignancies. Am J Med. 1986;81(5):871–82.
Ross C, Tingsgaard P, Jorgensen H, et al. Interferon treatment of cutaneous T-cell lymphoma. Eur J Haematol. 1993;51(2):63–72.
Vowels BR, Cassin M, Vonderheid EC, et al. Aberrant cytokine production by Sezary syndrome patients:cytokine secretion pattern resembles murine TH2 cells. J Invest Dermatol. 1992;99(1):90–4.
Vowels BR, Lessin SR, Cassin M, et al. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol. 1994;103(5):669–73.
Asadullah K, Do¨cke WD, Haeuler A, et al. Progression of mycosis fungoides is associated with increasing cutaneous expression of interleukin-10 mRNA. J Invest Dermatol 1996;107(6):833–7.
French LE, Huard B, Wysocka M, et al. Impaired CD40L signaling is a cause of defective IL-12 and TNF-a production in Se´zary syndrome: circumvention by hexameric soluble CD40L. Blood. 2005;105(1):219–25.
Yoo EK, Cassin M, Lessin SR, et al. Complete molecular remission during biologic response modifier therapy for Se´zary syndrome is associated with enhanced helper T type 1 cytokine production and natural killer cell activity. J Am Acad Dermatol. 2001;45(2):208–16.
Furudate S, Fujimura T, Kakizaki A, et al. Tumor-associated M2 macrophages in mycosis fungoides acquire immunomodulatory function by interferon alpha and interferon gamma. J Dermatol Sci. 2016;83(3):182–9.
Suchin KR, Cassin M, Gottleib SL, et al. Increased interleukin 5 production in eosinophilic Se´zary syndrome: regulation by interferon alfa and interleukin 12. J Am Acad Dermatol. 2001;44(1):28–32.
Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States cutaneous lymphoma consortium (USCLC). J Am Acad Dermatol. 2011;64(2):352–404.
Koeller JM. Biologic response modifiers: the interferon alfa experience. Am J Hosp Pharm. 1989;46(11 SUPPL. 2):S11–5.
Actimmue [package insert]. Roswell: Vidara Therapeutics; 2013.
Olsen EA. Interferon in the treatment of cutaneous Tcell lymphoma. Dermatol Ther. 2003;16(4):311–21.
Hughes CF, Khot A, McCormack C, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sezary syndrome: a comparative study of systemic therapy. Blood. 2015;125:71–81.
Suchin KR, Cucchiara AJ, Gottleib SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol. 2002;138:1054–60.
Sugaya M, Tokura Y, Hamada T, et al. Phase II study of i.v. interferon-gamma in Japanese patients with mycosis fungoides. J Dermatol 2014;41(1):50–6.
Straus DJ, Duvic M, Kuzel T, et al. Results of a phase II trial of oral bexarotene (Targretin) combined with interferon alfa-2b (Intron-A) for patients with cutaneous T-cell lymphoma. Cancer. 2007;109(9):1799–803.
Rook AH, Prystowsky MB, Cassin M, et al. Combined therapy for Sézary syndrome with extracorporeal photo chemotherapy and low-dose interferon alfa therapy. Clinical, molecular, and immunologic observations. Arch Dermatol. 1991;127(10):1535–40.
Kuzel TM, Roenigk HH Jr, Samuelson E, et al. Effectiveness of interferon alfa-2a combined with phototherapy for mycosis fungoides and the Sézary syndrome. J Clin Oncol. 1995;13(1):257–63.
Garcia-Vega Y, et al. Pharmacokinetic and pharmacodynamics characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol. 2012;13:20.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
No external funding was used in the preparation of this manuscript.
Conflict of interest
Robert Duffy, Tara Jennings, Saritha Kartan, Andrew Song, Wenyin Shi, Pierluigi Porcu, Onder Alpdogan, and Joya Sahu have no conflicts of interest that might be relevant to the contents of this manuscript.
Additional information
Robert Duffy and Tara Jennings contributed equally to this work.
Rights and permissions
About this article
Cite this article
Duffy, R., Jennings, T., Kartan, S. et al. Special Considerations in the Treatment of Mycosis Fungoides. Am J Clin Dermatol 20, 571–578 (2019). https://doi.org/10.1007/s40257-019-00431-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40257-019-00431-z